Cognition Disorders clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).
San Francisco, California and other locations
Our lead scientists for Cognition Disorders research studies include Adam Boxer.